High Quality Epalrestat

Supply 99% API High quality raw material epalrestat 82159-09-9

Information

Product Name epalrestat

Molecular Formula C15H13NO3S2

Molecular Weight 319.3986

CAS Registry Number 82159-09-9

Density 1.43g/cm3

Boiling point 516.8°C at 760 mmHg

Refractive index 1.705

Flash point 266.4°C                                        

Epalrestat is an aldose reductase inhibitor, used in the treatment of diabetic neuropathy.

Epalrestat is a carboxylic acid derivative and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in that it is a drug that contains a rhodanine group. Aldose reductase is the key enzyme in the polyol pathway whose enhanced activity is the basis of diabetic neuropathy. Aldose reductase inhibitors (ARI) target this enzyme. Out of the many ARIs developed, ranirestat and fidarestat are in the trial stage. Others have been discarded due to unacceptable adverse effects or weak efficacy. Epalrestat is the only ARI commercially available. It is easily absorbed into the neural tissue and inhibits the enzyme with minimum side effects.

Function

Epalrestat is an aldose reductase inhibitor. Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy.

Specification